Oseltamivir-Resistant Influenza Viruses A (H1N1) during 2007–2009 Influenza Seasons, Japan by Ujike, Makoto et al.
To monitor oseltamivir-resistant inﬂ  uenza  viruses  A 
(H1N1) (ORVs) with H275Y in neuraminidase (NA) in Ja-
pan during 2 inﬂ  uenza seasons, we analyzed 3,216 clini-
cal samples by NA sequencing and/or NA inhibition assay. 
The total frequency of ORVs was 2.6% (45/1,734) during 
the 2007–08 season and 99.7% (1,477/1,482) during the 
2008–09 season, indicating a marked increase in ORVs in 
Japan during 1 inﬂ  uenza season. The NA gene of ORVs in 
the 2007–08 season fell into 2 distinct lineages by D354G 
substitution, whereas that of ORVs in the 2008–09 season 
fell into 1 lineage. NA inhibition assay and M2 sequencing 
showed that almost all the ORVs were sensitive to zana-
mivir and amantadine. The hemagglutination inhibition test 
showed that ORVs were antigenetically similar to the 2008–
09 vaccine strain A/Brisbane/59/2007. Our data indicate 
that the current vaccine or zanamivir and amantadine are 
effective against recent ORVs, but continuous surveillance 
remains necessary.
I
nﬂ  uenza A and B viruses are major pathogens that repre-
sent a threat to public health with subsequent economic 
losses worldwide (1). Vaccination is the primary method for 
prevention; antiviral drugs are used mainly for prophylaxis 
and therapy. Currently, 2 classes of drugs, matrix 2 (M2) 
blockers and neuraminidase inhibitors (NAIs) are avail-
able, but M2 blockers such as amantadine and rimantadine 
are not commonly used because of the rapid generation of 
resistance and lack of efﬁ  cacy against inﬂ  uenza B virus 
(2–4). The NAIs zanamivir and oseltamivir are widely used 
because of effects against inﬂ  uenza A and B viruses and a 
low frequency of resistance. NAI virus surveillance studies 
by several groups have demonstrated that <1% of viruses 
tested show naturally occurring resistance to oseltamivir as 
of 2007 (5–10), indicating limited human-to-human trans-
mission of these viruses.
At the beginning of the 2007–08 inﬂ  uenza  season, 
however, detection of a substantially increased number of 
oseltamivir-resistant inﬂ  uenza viruses A (H1N1) (ORVs) 
was reported, mainly in countries in Europe where the 
prevalence varies, with the highest levels in Norway (67%) 
and France (47%) (11–14). These viruses showed a speciﬁ  c 
NA mutation with a histidine-to-tyrosine substitution at the 
aa 275 position (N1 numbering, H275Y), conferring high-
level resistance to oseltamivir. Most of these ORVs were 
isolated from NAI-untreated patients and retained similar 
ability of human-to-human transmission to oseltamivir-
sensitive inﬂ  uenza viruses A (H1N1) (OSVs) (10,15). In 
response to public health concerns about ORVs, the World 
Health Organization (WHO) directed Global Inﬂ  uenza 
Surveillance Network laboratories to intensify NAI surveil-
lance and announced regularly updated summaries of ORV 
data collected from each laboratory on its website (16). This 
site reported that the global frequency increased from 16% 
(October 2007–March 2008) to 44% (April 2008–Septem-
ber 2008) to 95% (October 2008–January 2009), indicating 
that ORVs have spread rapidly around the world.
Oseltamivir-Resistant Inﬂ  uenza 
Viruses A (H1N1) during 2007–2009 
Inﬂ  uenza Seasons, Japan
Makoto Ujike, Kozue Shimabukuro, Kiku Mochizuki, Masatsugu Obuchi, Tsutomu Kageyama, 
Masayuki Shirakura, Noriko Kishida, Kazuyo Yamashita, Hiroshi Horikawa, Yumiko Kato, 
Nobuyuki Fujita, Masato Tashiro, Takato Odagiri, and the Working Group for Inﬂ  uenza Virus 
Surveillance in Japan1
RESEARCH
926  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 16, No. 6, June 2010
Author afﬁ   liations: National Institute of Infectious Diseases, To-
kyo, Japan (M. Ujike, K. Shimabukuro, K. Mochizuki, M. Obuchi, 
T. Kageyama, M. Shirakura, N. Kishida, K. Yamashita, M. Tashiro, 
T. Odagiri); and National Institute of Technology and Evaluation, 
Tokyo (H. Horikawa, Y. Kato, N. Fujita)
DOI: 10.3201/eid1606.091623
1Members of the Working Group for Inﬂ  uenza Virus Surveillance in 
Japan are listed at the end of this article.Oseltamivir-Resistant Inﬂ  uenza Viruses, Japan
Japan has the highest annual level of oseltamivir usage 
per capita in the world, comprising >70% of world con-
sumption (10). Such high use of oseltamivir has raised con-
cerns about emergence of OSVs with increased resistance 
to this drug. Moreover, in Japan, 2 recent inﬂ  uenza seasons 
were dominated by inﬂ  uenza viruses A (H1N1) (Figure 1). 
If a high prevalence of ORVs is observed, primary selec-
tion of oseltamivir treatment for inﬂ  uenza patients should 
be reconsidered. Thus, monitoring ORVs is a serious pub-
lic health issue.
To estimate the frequency of ORVs and characterize 
these viruses, we analyzed 1,734 clinical samples isolated 
from the 2007–08 season and 1,482 isolates from the 2008–
09 season by NA sequencing and/or NAI inhibition assay. 
The total frequencies were 2.6% in the 2007–08 season 
and 99.7% in the 2008–09 season, indicating that ORVs 
increased dramatically in Japan.
Materials and Methods
Virus Testing
Inﬂ  uenza sentinel clinics send clinical specimens to 
local public health laboratories for virus isolation. Several 
culture tissues, including MDCK, Caco-2, and LLC-MK2, 
are used for virus isolation. Without successful viral iso-
lation, clinical specimens are analyzed directly. Inﬂ  uenza 
viruses were collected from all 47 prefectures in Japan for 
this study; 1,734 samples of inﬂ  uenza A (H1N1) were iso-
lated during the 2007–08 season (September 2007–August 
2008) and 1,482 samples of inﬂ  uenza A (H1N1) were iso-
lated in the 2008–09 season (September 2008–April 2009). 
During the 2007–08 season, viruses were isolated primarily 
after December 2007. All inﬂ  uenza viruses A (H1N1) were 
subjected to full or partial (nt 615–1076) NA sequencing 
to detect H275Y substitution on the N1 NA protein. Rep-
resentative inﬂ  uenza viruses A (H1N1), including ORVs 
and OSVs, were subjected to NA inhibition assay (number 
of tested viruses isolated during the 2007–08 and 2008–09 
seasons was 306 and 58, respectively), full NA sequencing 
(891 and 83), hemagglutinin (HA) 1 sequencing (299 and 
83), M2 sequencing (288 and 79), and hemagglutinin inhi-
bition (HI) test (187 and 59).
Sequence Analysis
The phylogenetic tree of NA and HA1 genes was con-
structed by neighbor-joining methods. The phylogenetic 
tree was described by representative ORVs and OSVs iso-
lated from several prefectures in Japan. Sequence informa-
tion for isolates from other countries was obtained from 
the Global Initiative on Sharing Avian Inﬂ  uenza Data and 
the Los Alamos National Laboratory database. All amino 
acid positions in the phylogenetic tree were described by 
N1 numbering.
NA Inhibition Assay
The chemiluminescent NA inhibition assay was per-
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 16, No. 6, June 2010  927 
Figure 1. Weekly cases of inﬂ  uenza and isolation of inﬂ  uenza viruses in the 2007–08 and 2008–09 seasons in Japan (as of July 2, 2009). 
The National Epidemiologic Surveillance of Infectious Diseases (NESID) Network comprises the Ministry of Health, Labor and Welfare; the 
National Institute of Infectious Diseases; 76 local public health laboratories; ≈3,000 pediatric clinics; and 2,000 internal medical clinics. The 
NESID Network monitored inﬂ  uenza activity during the 2007–08 season (week 36, September 2007–week 35, August 2008) and 2008–09 
season (week 36, September 2008–week 22, May 2009). Clinically diagnosed inﬂ  uenza-like cases were reported weekly by inﬂ  uenza 
sentinel clinics. Boldface line indicates weekly cases of inﬂ  uenza-like illness per inﬂ  uenza sentinel clinic (values shown in right bar). Bars 
indicate numbers of inﬂ  uenza A (H1N1) (yellow), A (H3N2) (blue), and B (red) isolates (values shown in left bar). Inﬂ  uenza activity started 
week 47 of 2007 and ﬁ  nished in week 14 of 2008 in the 2007–08 season and started week 49 of 2008 and ﬁ  nished in week 22 of 2009 
in the 2008–09 season. Among all inﬂ  uenza isolates, inﬂ  uenza A (H1N1) consisted of 81% during 2007–08 and 49% during 2008–09. 
Seasonal inﬂ  uenza surveillance showed that inﬂ  uenza viruses A (H1N1) dominated the 2 recent inﬂ  uenza seasons in Japan.RESEARCH
formed by using the NA Star Kit (Applied Biosystems, 
Tokyo, Japan) with slight modiﬁ  cations of the instructions 
provided by the manufacturer. The ﬁ  nal drug concentration 
ranged from 0.03 nmol/L to 6,500 nmol/L for oseltamivir 
and from 0.03 nmol/L to 12,500 nmol/L for zanamivir. 
Chemiluminescent light emission was measured by using 
an LB940 plate reader (Berthhold Technologies, Bad Wild-
bad, Germany). Drug concentrations required to inhibit NA 
activity by 50% (IC50) were calculated by a 4-parameter 
method using MikroWin 2000 version 4 software (Mik-
rotek Laborsysteme GmbH, Overath, Germany).
Hemagglutination Inhibition Test
The HI test was performed to evaluate the reactiv-
ity of ferret antiserum against 2008–09 vaccine strain A/
Brisbane/59/2009, as described by the WHO manual (17). 
Antiserum was treated by receptor-destroying enzyme II 
(Denka Seiken, Tokyo, Japan) and adsorbed with packed 
turkey erythrocytes before testing to prevent nonspeciﬁ  c 
reaction. A 0.5% suspension of turkey erythrocytes was 
used for the HI test. Viruses with >8-fold reduced HI titer 
to the homologous titer of A/Brisbane/59/2009 antiserum 
were regarded as antigenic variants.
Statistical Analysis
To determine the cutoff value between NAI-resistant 
(outlier) and -sensitive viruses, box-and-whisker plots 
were used. The cutoff value was deﬁ  ned as upper quartile 
+ 5.0×interquartile range from the 25th to 75th percentile. 
In this study, ORVs with H275Y were excluded from the 
overall population for statistical analysis. Outliers were ex-
cluded from the calculation of mean values and standard 
deviations for IC50.
Results
Geographic Distribution of ORVs during the 
2007–08 and 2008–09 Inﬂ  uenza Seasons
To estimate the frequency of inﬂ   uenza A (H1N1) 
ORVs in each prefecture of Japan, 1,734 isolates during 
the 2007–08 season and 1,482 isolates during the 2008–09 
season were collected from all prefectures and examined 
by NA sequencing to detect the H275Y mutation in NA 
protein. In the 2007–08 season, 45 viruses possessing 
H275Y mutation (total frequency of ORVs 2.6%; Figure 
2, panel A) were observed in 10 prefectures, indicating that 
the frequency of ORVs was signiﬁ  cantly lower than that 
in countries in Europe and the United States (8,11–14). 
In Tottori prefecture, however, 22 of 68 inﬂ  uenza viruses 
A (H1N1) tested possessed H275Y, showing a markedly 
higher frequency (32.4%) than that in other prefectures. 
In the 2008–09 season, however, ORVs were observed 
nationwide. Of 1,482 inﬂ  uenza viruses A (H1N1), 1,477 
viruses possessed a H275Y mutation, for a total frequency 
of 99.7% (Figure 2, panel B). These data show that ORVs 
increased dramatically in Japan from the 2007–08 season 
to the 2008–09 season.
Genetic Analysis
Inﬂ  uenza viruses A (H1N1) during 2007–08 fell into 
either clade 2B, including the current vaccine strain A/
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Figure 2. Geographic distribution of oseltamivir-resistant inﬂ  uenza 
viruses A (H1N1) (ORVs) with H275Y in Japan during the 2007–08 
and 2008–09 seasons. The total number of inﬂ  uenza A  (H1N1) 
isolates tested is described inside each prefecture. Total frequency in 
Japan was 2.6% (45/1,734) during the 2007–08 season, although a 
high frequency (32.4%) of ORVs was observed in Tottori prefecture 
(A). On the other hand, total frequency was 99.7% (1,477/1,482) 
during the 2008–09 season (B), indicating a drastic increase in 
ORVs in Japan from the 2007–08 season to the 2008–09 season. 
*Number of ORVs/number of subtype H1N1 isolates tested.Oseltamivir-Resistant Inﬂ  uenza Viruses, Japan
Brisbane/59/2007, or clade 2C, and almost all inﬂ  uenza 
viruses A (H1N1) during 2008–09 fell into clade 2B. 
Most ORVs with H275Y belong to clade 2B, which can 
be further divided into 2 distinct lineages by an aspartic 
acid to glycine substitution at aa 354: a Northern-Eu lin-
eage sharing 354G, which was ﬁ  rst isolated from coun-
tries in northern Europe and now represents most ORVs 
worldwide; and a Hawaii lineage sharing 354D, which 
was ﬁ  rst detected in Hawaii and was rarely isolated in a 
few countries during the 2007–08 season (online Appen-
dix Figure, www.cdc.gov/EID/content/16/6/926-appF.
htm). In the 2007–08 season, of 45 ORVs, 1 virus (A/
Yokohama/91/2007) isolated in November 2007 belonged 
to clade 2C, and 44 viruses fell into either the Hawaii lin-
eage or Northern-Eu lineage. Conversely, in the 2008–09 
season, all ORVs belonged to the Northern-Eu lineage, 
indicating that ORVs of the Northern-Eu lineage domi-
nated in the 2008–09 season in Japan.
In the Hawaii lineage, OSVs genetically close to 
ORVs were observed. The NA gene of some ORVs had 
only 1 nucleotide difference from that of OSV coun-
terparts (i.e., A/Tochigi/8/2008 and A/Tochigi/9/2008, 
A/Nagano/1100/2008 and A/Nagano/1071/2008, A/
Yamagata/68/2008 and A/Yamagata/41/2008, respec-
tively), and the other ORVs are also genetically close to 
OSVs from Japan (online Appendix Figure). These HA 
genes were also genetically identical or close together 
(online Appendix Figure), suggesting that almost all 
ORVs from Japan with the Hawaii lineage are derived 
from OSVs from Japan. On the other hand, in the North-
ern-Eu lineage, OSV counterparts were not observed, 
but foreign ORVs genetically close to ORVs from Japan 
were observed. During the 2007–08 season, the NA gene 
of ORVs from Japan was close to that of ORVs isolated 
from countries in Europe (i.e., A/Paris/0341/2007 and A/
England/26/2008). During the 2008–09 season, the ORVs 
from Japan, which shared A189T on HA protein, were 
further divided into 4 subclades (C-1 to C-4) by common 
amino acid changes on HA and/or NA (online Appendix 
Figure). ORVs from Japan in C-2 and C-3 were genetical-
ly close to the ORVs isolated from North America or Ha-
waii (e.g., A/Memphis/03/2008 and A/Hawaii/19/2008), 
whereas ORVs in C-1, representing most inﬂ  uenza  A 
(H1N1) viruses from the 2008–09 season in Japan, and 
ORVs in C-4 were close to ORVs isolated from South 
Africa and Australia in the Southern Hemisphere (e.g., A/
Kenya/1432/2008 and A/Victoria/501/2008). All ORVs 
except C-3 were isolated before the emergence of ORVs 
from Japan in each subclade. These ﬁ  ndings suggest that 
ORVs from Japan within a Northern-Eu lineage would 
not have emerged domestically but instead may have been 
introduced from various countries.
Antiviral Drug Susceptibility
Of the 364 viruses (306 isolates in the 2007–08 season 
and 58 isolates in the 2008–09 season) tested by NA in-
hibition assay, 101 possessed a H275Y substitution. With 
the NA inhibition assay, although precise IC50 values were 
calculated from a normal sigmoid curve (Figure 3, panels A 
and B), some viruses generated 2 types of unusual sigmoid 
curves (Figure 3, panels C and D) resulting from the mixed 
population of NAI-resistant and -sensitive viruses, as pre-
viously reported (18). Tentative IC50 values were calculated 
from type A curves (Figure 3, panel C) and included in 
overall statistical analysis, but values could not be calcu-
lated from type B curves (Figure 3, panel D). Later viruses 
were regarded as resistant candidates.
In the NA inhibition assay for oseltamivir, OSVs 
showed a mean IC50 ± SD of 0.10 ± 0.05 nmol/L (range 
0.01–0.35 nmol/L), and ORVs had a mean ± SD IC50 of 
67.7 ± 44.1 nmol/L (range 26.1–239.2 nmol/L), showing a 
reduction of >260-fold in susceptibility to oseltamivir. One 
OSV identiﬁ  ed as a statistical outlier (cutoff IC50, >0.40 
nmol/L; upper quartile + 5.0× interquartile range) showed 
a D151E substitution on the NA protein (Table 1).
In the NA inhibition assay for zanamivir, statisti-
cal analysis showed that 341 viruses were regarded as the 
zanamivir-sensitive viruses, with a mean ± SD IC50 of 0.40 
± 0.26 nmol/L (range 0.01–1.92 nmol/L), and 16 viruses 
(10 ORVs and 6 OSVs) were identiﬁ  ed as outliers (cutoff 
IC50, >1.99 nmol/L) (Table 1). Seven viruses (2 ORVs and 
5 OSVs) were regarded as resistant candidates from curve 
ﬁ  t patterns. NA-sequencing for these 23 viruses (12 ORVs 
and 11 OSVs) showed 2 types of amino acid changes on 
the NA protein. One virus, A/Tottori/16/2008 (OSV), pos-
sessed a Q136K substitution, showing a high IC50 (41.89 
nmol/L), and 19 of the other 22 viruses displayed an ami-
no acid change G, N, or V at the D151 position (Table 1). 
These data suggest that D151 changes have a substantial 
effect on sensitivity to zanamivir (and oseltamivir). More-
over, A/Tottori/44/2008 with H275Y and D151D/G substi-
tutions conferred high-level resistance to both NAIs (Figure 
3, panels A and B). However, a recent study reported that a 
D151E change was detected only after virus propagation in 
cell culture, but not in the original clinical specimen (19), 
suggesting a possible role of cell culture in selecting these 
D151 variant viruses. To further investigate D151 variants, 
available original clinical specimens of viruses with D151 
variation were subjected to NA sequencing, so that all D151 
variations (D151G/E/N) were not detected in the original 
clinical specimens (Table 1). We thus concluded that D151 
variants might not have emerged as a natural occurrence and 
all recent ORVs would retain sensitivity to zanamivir.
Susceptibility to M2 inhibitors was determined to ﬁ  nd 
established-resistant markers by M2-sequencing. The 367 
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viruses (288 isolates in the 2007–08 season; 79 isolates in 
the 2008–09 season) including 123 ORVs (45 and 78, re-
spectively) and 244 OSVs (243 and 1, respectively) were 
tested. Viruses belonging to clade 2B were sensitive to M2 
inhibitors, and viruses belonging to clade 2C were resistant 
to M2 inhibitors, so all ORVs except A/Yokohama/91/2007 
were sensitive to M2 inhibitors. A/Yokohama/91/2007 be-
longed to clade 2C and was the only virus resistant to both 
oseltamivir and M2 inhibitors.
Antigenic Characteristics
To estimate the reactivity of ORVs and OSVs to 
ferret antiserum against 2008–09 vaccine strain A/
Brisbane/59/2009, the HI test was performed. Good inhi-
bition was achieved in 76% of OSVs and 69% of ORVs 
by A/Brisbane/59/2009 ferret antiserum, and 22% of OSVs 
and 28% of ORVs showed a 4-fold reduction in HI titer 
to the homologous titer, respectively (Table 2). Only 2% 
and 3% of OSVs and ORVs showed a >8-fold reduction in 
HI titer to A/Brisbane/59/2009 ferret antiserum. These data 
demonstrated that OSVs and ORVs were anitigenitically 
indistinguishable from each other and were similar to the 
2008–09 vaccine strain A/Brisbane/59/2009.
High Frequency of ORVs in Tottori Prefecture 
during the 2007–08 Season
Tottori Prefecture is located in the western part of the 
main island of Japan. Comprising 19 cities and geographi-
cally divided into 3 areas, this prefecture has the lowest 
population in Japan (Figure 4, panel B). Despite a low 
frequency of only 2.6% in Japan during 2007–08 season, 
an unexpectedly high frequency (32.4%) of ORVs was 
observed in Tottori prefecture (Figure 2, panel A). ORVs 
from Tottori were collected from 4 cities in 2 areas with no 
systematic bias apparent in the sampling process (Figure 
4, panel B).
Phylogenetic analysis of NA genes showed that these 
ORVs formed 3 subclades (Figure 4, panel A): the ﬁ  rst with 
a Northern-Eu lineage sharing V75A and D354G (T-1); the 
second with a Hawaii lineage without common changes 
(T-2); and the third with a Hawaii lineage and sharing 
M188L (T-3). Among these, only OSVs genetically close 
930  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 16, No. 6, June 2010
Figure 3. Assessment of drug concentrations required to inhibit neuraminidase activity by 50% (IC50) for neuramindase inhibitors (NAIs). 
Normal sigmoid curves were generated for most tested viruses by a neuraminidase inhibition assay for oseltamivir (A) and zanamivir (B). 
Sensitive A/Gunma/55/2007 (blue), oseltamivir-resistant A/Kobe/49/2008 (red) with H275Y, zanamivir-resistant A/Tottori/16/2008 (green) 
with Q136K, and oseltamivir/zanamivir-resistant A/Tottori/44/2008 (orange) with H275Y and D151D/G are shown. Unusual sigmoid curves 
were sometimes generated by the mixed population of NAI-resistant and -sensitive viruses for zanamivir: A/Yokohama/74/2008 with 
D151D/G (C, type A curve); and A/Hiroshima/92/2008 with D151D/G (D, type B curve). Tentative IC50 values (nM), shown below each 
panel, were obtained from type A curves but not from type B curves. NA, not available; NC, negative control; PC, positive control.Oseltamivir-Resistant Inﬂ  uenza Viruses, Japan
to ORVs were observed in T-2, suggesting that ORVs in 
T-2 would be derived from OSVs in Tottori prefecture.
A mapping study for ORVs showed that all ORVs in 
the Hawaii lineage were collected from Tottori city only, 
primarily at the end of January, whereas ORVs with the 
Northern-Eu lineage were collected from 4 cities, includ-
ing Tottori city, during February and March. Genetically 
diverse ORVs belonging to T1-T3 were cocirculating only 
in Tottori city in the eastern area (Figure 4, panel B). The 
Tottori case raised concern about the possibility that these 
Tottori ORVs could survive to become an origin ORV 
for the 2008–09 season in Japan. However, phylogenetic 
analysis showed that all ORVs isolated during the 2008–09 
season were not genetically close to ORVs from Tottori 
(online Appendix Figure). As a result, all ORVs from Tot-
tori seemed to have been eliminated in the 2007–08 season, 
and ORVs that may have been introduced from other coun-
ties were circulating during 2008–09 in Japan.
Discussion
Our study demonstrated that ORVs dramatically in-
creased in Japan from the 2007–08 season (2.6%) to the 
2008–09 season (99.7%). All tested ORVs showed a re-
duction of >260-fold in susceptibility to oseltamivir by NA 
inhibition assay. On the other hand, almost all ORVs re-
mained sensitive to the other antiviral-drugs, e.g., zanami-
vir, and M2 inhibitors. HI testing suggested that the current 
vaccine, A/Brisbane/59/2008, would be effective against 
recent ORVs. In addition, recent studies have reported that 
symptoms and hospitalization rates of patients infected 
with ORVs are no different from those seen with OSVs 
(14,20).
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Table 1. Influenza virus A (H1N1) outliers to oseltamivir and/or zanamivir, Japan* 
Strain
Sequence change(s) 
Clinical
specimen
Curve fit‡ 
IC50, nmol/L 
D151 H275 Q136  D151  Oseltamivir Zanamivir
Oseltamivir outlier 
 A/YAMAGATA/28/2008  D/E† H Q NA Normal  0.55 0.60
Zanamivir outlier candidates 
 A/TOTTORI/16/2008  D H K NA Normal  0.08 41.89 
 A/TOTTORI/60/2008  D Y Q NA Normal  113.86  3.64
 A/KOBE/31/2008  D Y Q NA Type  A  26.05  2.75
 A/KOBE/32/2008  D Y Q NA Type  A  135.85  3.56
 A/MIE/13/2008  D/G H Q D Type  A  0.18 14.80 
 A/YOKOHAMA/75/2007  D/G H Q NA Type  A  0.13 6.53
 A/HAMAMATSU/33/2008  D/G H Q NA Type  A  0.13 6.15
 A/TOCHIGI/30/2008  D/G H Q NA Type  A  0.13 4.32
 A/YOKOHAMA/74/2007  D/G H Q NA Type  A  0.12 2.81
 A/HIROSHIMA/92/2007  D/G H Q NA Type  B  0.07 NA
 A/MIE/9/2008  D/G H Q D Type  B  0.08 NA
 A/MIE/1/2008  D/G H Q D Type  B  0.16 NA
 A/MIE/14/2008  D/G H Q D Type  B  0.08 NA
 A/YAMAGATA/60/2008  D/G H Q NA Type  B  0.19 NA
 A/SAPPORO/64/2008  D/G Y Q NA Type  B  147.90  NA
 A/TOTTORI/44/2008  D/G Y Q NA Normal§  180.06  84.42 
 A/HIROSHIMA/44/2008  D/N  Y Q NA Type  A  239.23  2.26
 A/YOKOHAMA/79/2008  D/N  Y Q NA Type  A  167.66  2.28
 A/HIROSHIMA/46/2008  D/N  Y Q NA Type  A  190.35  2.40
 A/HIROSHIMA/45/2008  D/N  Y Q NA Type  A  169.92  3.34
 A/MIE/1/2009  D/N  Y Q NA Type  A  231.78  3.55
 A/HIROSHIMA/47/2008  D/N  Y Q NA Type  A  106.19  4.24
 A/YOKOHAMA/96/2008  D/V Y Q NA Type  B  126.50  NA
Zanamivir sensitive
 A/MIE/18/2008  D/E¶ H Q D Normal  0.35 1.06
 A/MIE/21/2008  D/N  H Q D Normal  0.22 1.18
IC50 mean of sensitive viruses  0.10 ± 0.05  0.40 ± 0.26 
Cutoff IC50 values (UQ +5.0 IQR)  0.40 1.99
*IC50, drug concentrations required to inhibit neuraminidase activity by 50%; UQ, upper quartile; IQR, interquartile range; NA, not available. Oseltamivir-
resistant viruses with H275Y were excluded from overall population in statistical analysis of oseltamivir. 
†Mixture of D151 and D151 variants. 
‡Curve fit patterns were evaluated based on Figure 3, panels C (Type A) and D (Type B). Although the viruses with D151D/G tend to generate both 
patterns from repeat testing for the same samples, type B was selected in this case. 
§Although A/TOTTORI/44/2008 showed mixed population of D151D/G, it tended to show a normal curve fit (Figure 3, panel B). 
¶The IC50 values of most viruses with D151D/E tend to be higher than mean IC50 values but do not exceed the cutoff value. RESEARCH
Japan has the largest per capita use of oseltamivir 
(>70%) in the world (10). Because this use could cause 
efﬁ  cient selection of ORVs in individual patients, Japan 
might be the initial site of worldwide spread of ORVs. 
However, long-term NAI surveillance in Japan during 
1996–2007 and recent surveillance showed a low frequen-
cy of NAI-resistant viruses for any strains and subtypes 
(10,21,22), suggesting that transmissibility of ORVs se-
lected by drug pressure was remarkably decreased. In addi-
tion, previous NAI surveillance (5–10) and several animal 
studies (23–26) also suggested that NAI-resistant viruses 
would become defective viruses with attenuated infectiv-
ity and transmissibility to human. In contrast, despite little 
NAI use, a high emergence of ORVs has been detected in 
several countries in Europe since November 2007. These 
ORVs had as efﬁ  cient transmissibility as OSVs in human-
to-human transmission, resulting in worldwide spread in a 
short period of time. Although whether the initial ORV de-
tected in Norway in the 2007–08 season appeared because 
of NAI drug pressure is unknown, those ORVs may have 
obtained amino acid changes on NA and/or other proteins 
to compensate for the defect, in addition to the H275Y sub-
stitution on the NA protein. Most ORVs belong genetically 
to the Northern-Eu lineage in clade 2B, suggesting that the 
gene constellation may contain a big advantage to retain 
infectivity and transmissibility.
An interesting question arose as to where the ORVs in 
Japan originated. In the Hawaii lineage, almost all ORVs 
in Japan would be derived from OSVs in Japan because 
the NA gene of ORVs was similar to OSV counterparts 
isolated at similar times or from similar regions (online 
Appendix Figure). On the other hand, in the Northern-Eu 
lineage, ORVs in Japan would have been introduced from 
other countries. In 2007–08, almost all ORVs would be im-
ported from countries in Europe. In 2008–09, the ORVs in 
C-1, which comprised most isolates in 2008–09, and ORVs 
in C-4 were genetically similar to ORVs isolated from the 
Southern Hemisphere. Because inﬂ  uenza activity in the 
Southern Hemisphere occurs half a year earlier than that in 
the Northern Hemisphere, most ORVs in Japan conceivably 
could have been imported from the Southern Hemisphere. 
ORVs in C-2 and C-3 were genetically similar to ORVs 
isolated in North America and Hawaii, but the collection 
month of ORVs in C-3 were similar to each other, suggest-
ing that ORVs in C-3 might be derived from an unknown 
common origin ORV. The ORVs obtained during 2008–09 
were not genetically similar to any ORVs isolated in Tot-
tori during 2007–08, indicating that ORVs from Tottori had 
been eliminated and had not formed the origin ORVs for 
the 2008–09 season in Japan. As for A/Yokohama/91/2007 
belonging to clade 2C, the patient from which this virus 
was isolated was known to have taken oseltamivir before 
sampling (22), indicating that selective drug pressure in 
this person might have selected for this ORV.
In the NA inhibition assay for zanamivir, some virus-
es, including ORVs and OSVs, showed reduced sensitiv-
ity to zanamivir. NA sequencing of these viruses showed 2 
types of amino acid changes. One virus, A/Tottori/16/2008 
(OSV), possessed a Q136K substitution, which reportedly 
confers resistance to zanamivir (27,28). Conversely, most 
of the other viruses possessed D151 G/V/N. The amino 
acid changes D151 to N or E among subtype H1N1 viruses 
and to A, G, E, N, or V among H3N2 have been reported 
(7,8,19), and viruses with D151 substitutions often exhibit 
reduced sensitivity to NAIs (8,19,29). However, a recent 
study reported a possible role for cell culture in select-
ing these D151 variant viruses (19). In the present study, 
D151 variations (D151G/E/N) also were not detected from 
available original clinical specimens (Table 1), supporting 
the previous ﬁ  nding. We thus concluded that viruses with 
D151 variations would not have emerged naturally, and all 
ORVs would remain sensitive to zanamivir.
By sequencing of M2 gene, we conﬁ  rmed that almost 
all Japanese ORVs belonging to clade 2B retained sensi-
tive genotype to M2 inhibitors, consistent with previously 
reports that recent clade 2B viruses are sensitive to M2 in-
hibitors, but clade 2C viruses are resistant (27).
During the 2007–09 seasons, we also addressed NAI 
surveillance for A/H3N2 and type B circulating in Japan 
and identiﬁ  ed no viruses resistant to both NAIs. Converse-
ly, in March and early April 2009, a new swine-origin in-
ﬂ  uenza virus A (H1N1) (now known as pandemic [H1N1] 
2009 virus) emerged in Mexico and the United States and 
spread rapidly to many countries, including Japan (30–33). 
In June 2009, detection of pandemic (H1N1) 2009 virus 
with H275Y on the NA protein was reported from Den-
mark, Hong Kong Special Administrative Region, People’s 
Republic of China, and Japan, but all ORVs of pandemic 
(H1N1) 2009 virus emerged as sporadic cases with no evi-
dence of efﬁ  cient human-to-human transmission (34). Al-
though oseltamivir remains a valuable drug for treatment 
of pandemic (H1N1) 2009, many ORVs were isolated 
after prophylaxis with a half dose of the drug. Therefore, 
prophylaxis with oseltamivir may not be recommended as 
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Table 2. Antigenic characterization of oseltamivir-resistant and oseltamivir-sensitive influenza virus A (H1N1), Japan, 2007–2009 
Antiserum Low to homologous titer, -fold*  No. (%) sensitive, n = 169  No. (%) resistant, n = 77 
A/Brisbane/59/2007  <2 128 (76)  53 (69) 
4 36 (22)  22 (28) 
>8 3 (2)  2 (3) 
*Viruses with >8-fold reduced hemagglutinin inhibition titer to homologous titer were regarded as an antigenic variant. Oseltamivir-Resistant Inﬂ  uenza Viruses, Japan
stated by WHO (35). Rapid and continuous monitoring of 
NAI-resistant viruses, including pandemic (H1N1) 2009 
virus, and dissemination of the ﬁ  ndings in timely manner 
remains essential.
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Figure 4. Phylogenetic analysis of inﬂ  uenza A (H1N1) neuraminidase 
genes (A) and geographic distribution of oseltamivir-resistant viruses 
(ORVs) (B) isolated from Tottori Prefecture, Japan, 2007–08. ORVs 
fell into either Northern-Eu lineage (red) or Hawaii lineage (blue); 
Tottori ORVs and current vaccine strains are indicated by black and 
purple, respectively. A) ORVs formed 3 subclades: T-1, sharing 
V75A and D354G; T-2, without common changes; and T-3, sharing 
M188L. Sampling dates are given after each strain name. Scale 
bars indicates nucleotide substitutions per site. B) Tottori Prefecture 
is geographically divided into 3 areas, comprising 19 cities. ORVs 
from Tottori were collected from 4 cities over 2 areas. The sampling 
month for each ORV is indicated by a triangle (January), circle 
(February), or square (March). *Zanamivir resistant.RESEARCH
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